FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Nippon Shokubai to Boost China Output of EV Battery Electrolyte Fivefold by 2027

By

Japanese chemical firm Nippon Shokubai (TYO:4114) intends to significantly boost its production capacity in China for an electrolyte that prolongs the lifespan of lithium-ion batteries used in EVs and energy storage systems, Nikkei Asia reported Tuesday.

A Chinese affiliate, in which Nippon Shokubai owns a 38% stake, will expand a Hunan province facility to raise annual output from 2,400 metric tons to 12,400 tons in fiscal 2027, without additional investment from the Japanese parent, the publication said.

The electrolyte, LiFSI, extends battery life by 1.6 times compared to the conventional LiPF6, reduces charging time, and improves low-temperature performance, though mass production is needed to lower its currently higher cost, the news daily said.

Demand for electrolytes in China is shifting, with storage batteries now accounting for 30-40% of sales, up from roughly 20% previousl, as renewable energy expands, while domestic Chinese producers are gaining market share, the report said.

Despite U.S. EV demand slowdown delaying a North American plant, Nippon Shokubai remains committed to battery materials, aiming to boost total capacity tenfold by 2030 with the China expansion as a key step, it added.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA